Hypothermia-induced hyperphosphorylation: A new model to study tau kinase inhibitors

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Bretteville, Alexis ^a,b   Marcouiller, Fraņois ^a,b   Julien, Carl ^a,b   El Khoury, Noura B ^a,b   Petry, Franck R ^a,b   Poitras, Isabelle ^a,b   Mouginot, Didier ^a,b   Lévesque, Georges ^a,b   Hébert, Sébastien S ^a,b   Planel, Emmanuel ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b Centre de Recherche du Centre Hospitalier   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CHLORIDE; PROTEIN KINASE INHIBITOR; TAU PROTEIN KINASE; TAU-PROTEIN KINASE;

ANESTHESIA; ANIMAL; ARTICLE; BRAIN; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FEMALE; HYPOTHERMIA; MALE; METABOLISM; MOUSE; PHOSPHORYLATION;

ANESTHESIA; ANIMALS; BRAIN; CELL LINE; CYCLIN-DEPENDENT KINASE 5; DRUG EVALUATION, PRECLINICAL; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HYPOTHERMIA; LITHIUM CHLORIDE; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS;

EID: 84863442375     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00480     Document Type: Article

References (55)

1. Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8, 429-31 (1995).
2. Glenner, G. G. & Wong, C. W. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890 (1984). (Pubitemid 14104991)
3. Iqbal, K., Grundke-Iqbal, I., Zaidi, T., Ali, N. &Wisniewski, H. M. Are Alzheimer neurofibrillary tangles insoluble polymers? Life Sci 38, 1695-700 (1986). (Pubitemid 16072427)
4. Brion, J. P., Couck, A. M., Passareiro, E. & Flament-Durand, J. Neurofibrillary tangles of Alzheimer's disease: An immunohistochemical study. J Submicrosc Cytol 17, 89-96 (1985). (Pubitemid 15158027)
5. Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I. & Iqbal, K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 98, 6923-8 (2001). (Pubitemid 32538318)
6. Hundelt, M. et al. Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation. Neurobiol Aging 32, 991-1006 (2011).
7. Hanger, D. P., Anderton, B. H. & Noble, W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-9 (2009).
8. Trojanowski, J. Q. & Lee, V. M. Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: Focusing on phosphatases. FASEB J 9, 1570-6 (1995). (Pubitemid 26012845)
9. Gong, C. X., Singh, T. J., Grundke-Iqbal, I. & Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61, 921-7 (1993). (Pubitemid 23241228)
10. Sontag, E. et al. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 63, 287-301 (2004). (Pubitemid 38429026)
11. Pei, J. J. et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58, 1010-9 (1999).
12. Planel, E., Sun, X. & Takashima, A. Role of GSK-3 beta in Alzheimer's disease pathology. Drug Development Research 56, 491-510 (2002). (Pubitemid 35168326)
13. Pei, J.-J. et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Research 797, 267-277 (1998). (Pubitemid 28332739)
14. Noble, W. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad SciUS A 102, 6990-5 (2005). (Pubitemid 40675429)
15. Gravitz, L. Drugs: A tangled web of targets. Nature 475, S9-11 (2011).
16. Planel, E. et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: Implications for Alzheimer's disease. J Neurosci 24, 2401-11 (2004). (Pubitemid 38327953)
17. Planel, E. et al. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 27, 3090-3097 (2007). (Pubitemid 46474135)
18. Planel, E. et al. Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci 28, 12798-807 (2008).
19. Planel, E. et al. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J 23, 2595-604 (2009).
20. Bhat, R. V., Budd Haeberlein, S. L. & Avila, J. Glycogen synthase kinase 3: A drug target for CNS therapies. J Neurochem 89, 1313-1317 (2004). (Pubitemid 38802652)
21. Gong, C. X., Lidsky, T., Wegiel, J., Grundke-Iqbal, I. & Iqbal, K. Metabolically active rat brain slices as a model to study the regulation of protein phosphorylation in mammalian brain. Brain Res Brain Res Protoc 6, 134-40 (2001). (Pubitemid 32167156)
22. Bhat, R. et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278, 45937-45945 (2003). (Pubitemid 37432740)
23. Sessler, D. I. Perianesthetic thermoregulation and heat balance in humans. FASEB J 7, 638-44 (1993). (Pubitemid 23163598)
24. Run, X., Liang, Z. & Gong, C.-X. Anesthetics and tau protein: Animal model studies. J Alzheimers Dis 22 Suppl 3, 49-55 (2010).
25. Papon, M.-A., Whittington, R. A., El-Khoury, N. B. & Planel, E. Alzheimer's disease and anesthesia. Front Neurosci 4, 272 (2011).
26. Augustinack, J., Schneider, A., Mandelkow, E.-M. & Hyman, B. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathologica 103, 26-35 (2002). (Pubitemid 36075309)
27. Buerger, K. et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59, 627-629 (2002). (Pubitemid 34920005)
28. Hampel, H. et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61, 95-102 (2004). (Pubitemid 38044645)
29. Braak, H.,Alafuzoff, I., Arzberger, T., Kretzschmar, H.&Del Tredici, K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389-404 (2006). (Pubitemid 44469160)
30. Goedert, M., Jakes, R., Qi, Z.,Wang, J. H. & Cohen, P. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J. Neurochem. 65, 2804-2807 (1995).
31. Liu, F., Grundke-Iqbal, I., Iqbal, K. & Gong, C.-X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-50 (2005). (Pubitemid 41579384)
32. Tian, Q. &Wang, J. Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals 11, 262-9 (2002). (Pubitemid 37494393)
33. Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q. & Lee, V.M. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168, 402-12 (2001). (Pubitemid 32289776)
34. Gong, C. X. et al. Phosphatase activity toward abnormally phosphorylated tau: Decrease in Alzheimer disease brain. J Neurochem 65, 732-8 (1995).
35. Hooper, C., Killick, R. & Lovestone, S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-9 (2008). (Pubitemid 351316776)
36. Maccioni, R. B., Otth, C., Concha II & Munoz, J. P. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem 268, 1518-27. (2001). (Pubitemid 32862683)
37. Whittington, R. A., Papon, M.-A., Chouinard, F. & Planel, E. Hypothermia and Alzheimer's disease neuropathogenic pathways. Curr Alzheimer Res 7, 717-25 (2010).
38. Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105 (2000).
39. Hamdane, M. et al. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem 278, 34026-34 (2003). (Pubitemid 37553239)
40. Han, P. et al. Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: A novel excitoprotective mechanism involving modulation of tau phosphorylation. J Neurosci 25, 11542-52 (2005). (Pubitemid 43098447)
41. Brandt, R., Hundelt, M. & Shahani, N. Tau alteration and neuronal degeneration in tauopathies: Mechanisms and models. Biochim Biophys Acta 1739, 331-354 (2005). (Pubitemid 40018549)
42. Arendt, T.,Holzer, M., Brückner, M. K., Janke, C.&Gärtner, U. The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer's disease. Neuroscience 85, 1337-40 (1998). (Pubitemid 28293435)
43. Mailliot, C., Bussière, T., Caillet-Boudin, M. L., Delacourte, A. & Buée, L. Alzheimer-specific epitope of AT100 in transfected cell lines with tau: Toward an efficient cell model of tau abnormal phosphorylation. Neurosci Lett 255, 13-6 (1998). (Pubitemid 28494141)
44. Nuydens, R. et al. Okadaic acid-induced apoptosis in neuronal cells: Evidence for an abortive mitotic attempt. J Neurochem 70, 1124-33 (1998). (Pubitemid 28113646)
45. Bretteville, A. & Planel, E. Tau aggregates: Toxic, inert, or protective species? J Alzheimers Dis 14, 431-436 (2008).
46. Spires-Jones, T. L., Kopeikina, K. J., Koffie, R. M., de Calignon, A. & Hyman, B. T. Are tangles as toxic as they look? J Mol Neurosci 45, 438-44 (2011).
47. Planel, E., Yasutake, K., Fujita, S. C. & Ishiguro, K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 276, 34298-306 (2001).
48. Henry, M., Grob, M. & Mouginot, D. Endogenous angiotensin II facilitates GABAergic neurotransmission afferent to the Na1-responsive neurons of the rat median preoptic nucleus. Am J Physiol Regul Integr Comp Physiol 297, R783-92 (2009).
49. Hamdane, M. et al. p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. 118, 1291Journal of cell science-8 (2005).
50. Jämsä, A., Hasslund, K., Cowburn, R. F., Bäckström, A. & Vasänge, M. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as amodel for Alzheimer's disease-like tau phosphorylation. Biochem Biophys Res Commun 319, 993-1000 (2004). (Pubitemid 38739418)
51. Weaver, C. L., Espinoza, M., Kress, Y. & Davies, P. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21, 719-27 (2000).
52. Jicha, G. A. et al. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem 69, 2087-95 (1997). (Pubitemid 27452756)
53. Otvos, L. et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39, 669-73 (1994).
54. Whittington, R. A. et al. Propofol directly increases tau phosphorylation. PLoS One 6, e16648 (2011).
55. Binder, L. I., Frankfurter, A. & Rebhun, L. I. The distribution of tau in the mammalian central nervous system. J Cell Biol 101, 1371-1378 (1985). (Pubitemid 16203754)